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Background:  Amyloid deposition in the heart is a devastating process that leads to heart failure, angina, and arrhythmias. Early treatment 
may improve outcomes but entails a delicate suspicion and multidisciplinary approach.
case:  A 74-year-old male presented with 8 months of progressive exercise intolerance and bilateral leg swelling. Medical history included 
old anterior MI with previous stenting, hypertension, and dyslipidemia. A stress echocardiography was negative a year ago. No prior history 
of valvular dysfunction, heart failure or significant arrhythmias. His medications included: Aspirin, Atorvastatin, Captopril and Metoprolol. 
Physical examination showed controlled blood pressure with signs of heart failure: basal lung crackles, elevated jugular venous pressure, 
bilateral leg edema and S4 gallop.
decision Making:  Echocardiography revealed severe concentric left ventricular (LV) hypertrophy with increased myocardial echogenicity, 
restrictive pattern of LV diastolic dysfunction with preserved ejection fraction and biatrial enlargement. Chest X-ray showed right sided 
pleural effusion. Cardiac peptides were elevated. Treatment for new onset diastolic heart failure was started using diuretics. Further 
evaluation of previous echocardiography and blood pressure logs signified an impressive worsening of LV wall mass despite satisfactory 
blood pressure control. Clinical suspicion for infiltrative myocardial process prompted further workup. Serum/Urine protein electrophoresis 
was unremarkable. Light chain assays showed higher serum Kappa levels. Abdominal fat pad biopsy showed no amyloidosis. Bone marrow 
biopsy with cytogenetic studies and immunohistochemistry showed no evidence of lymphoma or myeloma while in-situ hybridization 
showed kappa-restricted plasma cells, establishing the diagnosis of cardiac amyloidosis (AL type). Patient refused endomyocardial biopsy 
and treatment with Bortezomib and Dexamethasone was initiated.
conclusion:  New onset diastolic dysfunction in patients with controlled risk factors should raise a clinical suspicion for infiltrative 
myocardial diseases.
